Wong T Y, Chan J C, Poon E, Li P K
Department of Medicine and Therapeutics, Chinese University of Hong Kong, Shatin, Hong Kong.
Am J Kidney Dis. 1999 Jun;33(6):1064-70. doi: 10.1016/S0272-6386(99)70143-5.
The prevalence of diabetic nephropathy is greater in nonwhite patients with type II diabetes, including the Chinese, and genetic variation appears to have a role. We examined angiotensin-converting enzyme (ACE) DD/II and angiotensinogen (Atg) M235T polymorphism in a cohort of Chinese patients with type II diabetes with an average duration of diabetes of 14 years. Group A (n = 88) did not have significant diabetic nephropathy (creatinine levels </= 130 micromol/L [</=1.48 mg/L], without macroalbuminuria), and group B (n = 80) had significant diabetic nephropathy (macroalbuminuria or creatinine level >130 micromol/L [>1.48 mg/d], and those undergoing dialysis). The two groups were matched in different aspects, including age, duration of diabetes, blood pressure, and glycemic control. The results showed: (1) no difference of genotype distribution between groups A and B (DD:DI:II, 14%:45%:41% v 8%:38%:54%; P = 0.20; TT:TM/MM, 70%:30% v 76%:24%; P = 0.43), (2) no evidence of synergistic effect of ACE (DD/II) and Atg M235T gene polymorphisms, (3) no difference of allele frequencies between groups A and B (D:I, 36%:64% v 27%:73%; P = 0.20 and T:M, 86%:16% v 86%:14%; P = 0.73), and (4) ACE activity was greatest in patients with DD genotype and least in those with II genotype (DD:DI:II = 66. 9 +/- 13.3 U/L:61.5 +/- 19.9 U/L:45.0 +/- 17.0 U/L; P < 0.005). The data do not support a role of ACE (DD/II) or Atg M235T polymorphism in the development of diabetic nephropathy in Chinese patients with type II diabetes, and no synergistic effect was found between them. Greater ACE activity was associated with DD genotype, and its role in diabetic nephropathy remains to be elucidated.
在包括中国人在内的非白人II型糖尿病患者中,糖尿病肾病的患病率更高,而且基因变异似乎起到了一定作用。我们在一组糖尿病平均病程为14年的中国II型糖尿病患者中检测了血管紧张素转换酶(ACE)DD/II和血管紧张素原(Atg)M235T基因多态性。A组(n = 88)无明显糖尿病肾病(肌酐水平≤130微摩尔/升[≤1.48毫克/升],无大量蛋白尿),B组(n = 80)有明显糖尿病肾病(大量蛋白尿或肌酐水平>130微摩尔/升[>1.48毫克/分升],以及正在接受透析的患者)。两组在年龄、糖尿病病程、血压和血糖控制等不同方面进行了匹配。结果显示:(1)A组和B组之间基因型分布无差异(DD:DI:II,14%:45%:41%对8%:38%:54%;P = 0.20;TT:TM/MM,70%:30%对76%:24%;P = 0.43),(2)没有证据表明ACE(DD/II)和Atg M235T基因多态性有协同作用,(3)A组和B组之间等位基因频率无差异(D:I,36%:64%对27%:73%;P = 0.20以及T:M,86%:16%对86%:14%;P = 0.73),以及(4)DD基因型患者的ACE活性最高,II基因型患者的ACE活性最低(DD:DI:II = 66.9±13.3单位/升:61.5±19.9单位/升:45.0±17.0单位/升;P < 0.005)。这些数据不支持ACE(DD/II)或Atg M235T基因多态性在我国II型糖尿病患者糖尿病肾病发生中起作用,且未发现它们之间有协同作用。较高的ACE活性与DD基因型相关,其在糖尿病肾病中的作用仍有待阐明。